Published in Mol Cancer on December 13, 2005
DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer (2007) 1.11
Quantitation of DNA methylation by melt curve analysis. BMC Cancer (2009) 1.06
Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer (2008) 0.97
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS One (2010) 0.94
Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today (2013) 0.92
Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas. PLoS One (2011) 0.91
Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol (2008) 0.87
Identification of a DNA methylome profile of esophageal squamous cell carcinoma and potential plasma epigenetic biomarkers for early diagnosis. PLoS One (2014) 0.87
Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma. Chin J Cancer (2012) 0.85
Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation. J Transl Med (2014) 0.81
IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation. Br J Cancer (2013) 0.80
Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomedicine (2013) 0.79
Metallothionein-3 Increases Triple-Negative Breast Cancer Cell Invasiveness via Induction of Metalloproteinase Expression. PLoS One (2015) 0.79
Propofol exerts hippocampal neuron protective effects via up-regulation of metallothionein-3. Neurol Sci (2012) 0.78
Role of metallothioneins in benign and malignant thyroid lesions. Thyroid Res (2012) 0.78
Metallothionein 2 regulates endothelial cell migration through transcriptional regulation of vegfc expression. Angiogenesis (2015) 0.78
Metallothionein 3 expression in normal skin and malignant skin lesions. Pathol Oncol Res (2015) 0.75
Maternal dietary zinc supplementation enhances the epigenetic-activated antioxidant ability of chick embryos from maternal normal and high temperatures. Oncotarget (2017) 0.75
In Vitro Protective Effects of Lycium barbarum Berries Cultivated in Umbria (Italy) on Human Hepatocellular Carcinoma Cells. Biomed Res Int (2016) 0.75
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res (1997) 9.94
Metallothionein. Annu Rev Biochem (1986) 8.12
Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J (1992) 3.43
Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol (1994) 2.97
The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron (1991) 2.05
Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol (1993) 1.95
Inactive chromatin spreads from a focus of methylation. Mol Cell Biol (1993) 1.83
Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res (1997) 1.77
The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res (1998) 1.73
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer (2001) 1.23
Constitutive expression of metallothionein-III (MT-III), but not MT-I, inhibits growth when cells become zinc deficient. Toxicol Appl Pharmacol (1995) 1.15
Fusion of the NUP98 gene with the LEDGF/p52 gene defines a recurrent acute myeloid leukemia translocation. BMC Genet (2001) 1.07
Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect (2000) 1.05
Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis (2003) 1.04
Mammalian metallothionein. Biol Trace Elem Res (1990) 0.99
Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol (2001) 0.95
Modulation of metallothionein-III mRNA content and growth rate of rat C6-glial cells by transfection with human 5-HT1D receptor genes. Biochem Biophys Res Commun (1995) 0.95
Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate (2002) 0.89
Protective effect of metallothionein-III on DNA damage in response to reactive oxygen species. Biochim Biophys Acta (2002) 0.86
Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells. Breast Cancer Res Treat (2003) 0.85
Aspirin and indomethacin for the prevention of experimental port-site metastases. Surg Endosc (2004) 0.80
Method for optimizing methylation-specific PCR. Biotechniques (2003) 0.78
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell (2011) 2.49
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Accuracy of PET-CT in predicting survival in patients with esophageal cancer. World J Surg (2012) 2.26
Results of laparoscopic antireflux operations in patients who have Barrett's esophagus. Chest Surg Clin N Am (2002) 1.95
High-risk human papillomavirus in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.83
An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg (2007) 1.79
Laparoscopic repair of very large hiatus hernia with sutures versus absorbable mesh versus nonabsorbable mesh: a randomized controlled trial. Ann Surg (2015) 1.64
Improving surveillance for Barrett's oesophagus. BMJ (2006) 1.60
Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc (2004) 1.56
Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res (2008) 1.50
Five-year follow-up of a multicenter, double-blind randomized clinical trial of laparoscopic Nissen vs anterior 90 degrees partial fundoplication. Arch Surg (2010) 1.48
The effect of long-term control of reflux by fundoplication on aberrant deoxyribonucleic acid methylation in patients with Barrett esophagus. Ann Surg (2010) 1.46
Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt. Ann Surg (2007) 1.44
Recurrent symptoms after fundoplication with a negative pH study--recurrent reflux or functional heartburn? J Gastrointest Surg (2008) 1.44
Objective outcomes 14 years after laparoscopic anterior 180-degree partial versus nissen fundoplication: results from a randomized trial. Ann Surg (2013) 1.44
Laparoscopic anterior 90 degree fundoplication for reflux or large hiatus hernia. ANZ J Surg (2008) 1.43
Galanin mediates the pathogenesis of cerulein-induced acute pancreatitis in the mouse. Pancreas (2010) 1.43
Isolated tumor cells in esophageal cancer: implications for the surgeon and the pathologist. Ann Surg (2010) 1.42
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39
Laparoscopic placement of peritoneal dialysis catheters: 7 years experience. ANZ J Surg (2003) 1.32
Minimally invasive versus open esophagectomy for patients with esophageal cancer. Ann Thorac Surg (2009) 1.30
Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci (2013) 1.24
Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol (2010) 1.24
Postsurgical infections are reduced with specialized nutrition support. World J Surg (2006) 1.22
Influence of follow-up methodology and completeness on apparent clinical outcome of fundoplication. Am J Surg (2003) 1.18
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res (2013) 1.17
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg (2011) 1.14
The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. Int J Cancer (2012) 1.13
Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol (2008) 1.12
Randomized trial of division versus nondivision of the short gastric vessels during laparoscopic Nissen fundoplication: 10-year outcomes. Ann Surg (2008) 1.10
Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicol Sci (2011) 1.09
Transoral incisionless fundoplication 2.0 procedure using EsophyX™ for gastroesophageal reflux disease. J Gastrointest Surg (2010) 1.08
Responses of human clasp and sling fibers to neuromimetics. J Gastroenterol Hepatol (2004) 1.08
Division of short gastric vessels at laparoscopic nissen fundoplication: a prospective double-blind randomized trial with 5-year follow-up. Ann Surg (2002) 1.07
Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep (2011) 1.07
Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res (2005) 1.07
Quantitation of DNA methylation by melt curve analysis. BMC Cancer (2009) 1.06
Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncol Rep (2009) 1.01
Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg (2007) 1.00
Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg (2009) 1.00
Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer (2008) 0.97
MicroRNAs and esophageal cancer--implications for pathogenesis and therapy. Curr Pharm Des (2013) 0.97
Current status and future perspective of general surgical trainees in the Netherlands. World J Surg (2007) 0.97
Barrett's esophagus. J Gastroenterol Hepatol (2011) 0.97
Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol (2011) 0.96
Laparoscopic anterior 180-degree versus nissen fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg (2013) 0.96
Acute ruptured esophageal duplication cyst. Dis Esophagus (2004) 0.95
Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control (2012) 0.95
MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol (2010) 0.95
Assessment of an electronic voting system within the tutorial setting: a randomised controlled trial [ISRCTN54535861]. BMC Med Educ (2005) 0.95
Multicenter, prospective, double-blind, randomized trial of laparoscopic nissen vs anterior 90 degrees partial fundoplication. Arch Surg (2004) 0.95
Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol (2011) 0.95
Crystal structure of glycerophosphodiester phosphodiesterase (GDPD) from Thermoanaerobacter tengcongensis, a metal ion-dependent enzyme: insight into the catalytic mechanism. Proteins (2008) 0.94
Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma. PLoS One (2011) 0.94
Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction. ANZ J Surg (2005) 0.94
MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus. J Gastrointest Surg (2009) 0.92
Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol (2015) 0.91
Preoperative prediction of long-term outcome following laparoscopic fundoplication. ANZ J Surg (2002) 0.90
Five-year outcome after laparoscopic anterior partial versus Nissen fundoplication: four randomized trials. Ann Surg (2012) 0.90
A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture. Biol Cell (2010) 0.89
Impact of gastro-esophageal reflux on mucin mRNA expression in the esophageal mucosa. J Gastrointest Surg (2008) 0.88
miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol (2011) 0.88
The effect of obesity on the outcome of laparoscopic antireflux surgery. J Gastrointest Surg (2009) 0.88
Effect of sex on symptoms associated with gastroesophageal reflux. Arch Surg (2011) 0.88
Impact of gender and age on the long-term outcome of laparoscopic fundoplication. World J Surg (2009) 0.87
Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol (2008) 0.87